An exclusive distribution agreement with Uk cbd distributor Vitality CBD is an exciting step towards medical kiwi plans to enable New Zealanders to have access to high-quality, affordable and affordable medical cannabis products. In the agreement, the company`s high-quality CBD isolate and broad-spectrum CBD oil are sold to wholesalers and manufacturers of medical CPG products through the GMP CBD Export Global certified laboratory owner. David Attard, Chief Executive Officer of PharmaCielo, said: “The agreement with CBD Export Global is part of the second phase of PharmaCielo`s growth strategy, which completes the first phase in which we launched one of the largest growing and mining activities in Colombia and launched global distribution, and now, in the second phase, the distribution network is expanding , as production volumes increase every day to bring our high-quality medical CBD extracts to global markets. Forward-Looking Statements: This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or future benefits. Statements that are not purely historical are forward-looking statements and contain statements about the beliefs, Future plans, perspectives, expectations or intentions, including words or phrases such as “anticipate,” “be,” “objectively,” “could,” “could,” “may,” “may,” “intention,” “wait,” “estimate,” “estimate,” “potential,” “is designed for,” “project,” “continue,” or similar expressions, which will propose future results or negative or similar variations. These forward-looking statements include, but are not limited to, that the company`s products are accepted by the Asian market, that the company will be able to produce and sell its products during the fourth quarter of calendar year 2019 and that the joint venture will be able to resume the logistics of product distribution. We are also exposed to a variety of additional risks, as indicated in our SEC submissions on www.SEC.gov. About CBD Asia GroupCBD Group Asia (“CGA”) is opening up growth paths in emerging cannabidiol (CBD) embryonic markets in Asia. CGA is positioning itself as a channel in this region by investing in Asian CBD hyper-growth stories and distributing growth-oriented North American cbd brands.

CGA is taking advantage of its management team`s decades of experience in investing, distributing and marketing consumer products in Asia to grow and develop within the Asian cbd. NOW THEREFORE, for other good and valuable counterparties whose receipt and sufficiency are heres notably recognized by the implementation of this Agreement, the parties who wish to be bound by law agree on the following way: BELFAST, Northern Ireland, Aug.